Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy

Gene Therapy

Volumn 8, Issue 13, 2001, Pages 1005-1010

  Heine, D ^a   Muller R ^a   Brusselbach S ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Doxorubicin; GDEPT; HMR 1826; Prodrug; glucuronidase

Indexed keywords

BETA GLUCURONIDASE; DOXORUBICIN; LYSOSOME ENZYME; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PRODRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG TRANSPORT; ENZYME BINDING; ENZYME RELEASE; EXTRACELLULAR SPACE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STEADY STATE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL MEMBRANE; CHORIOCARCINOMA; DOXORUBICIN; GENE THERAPY; GLUCURONATES; GLUCURONIDASE; HUMANS; LUNG NEOPLASMS; LYSOSOMES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034947012     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301474     Document Type: Article

References (31)

1. Pharmacology of drugs that alter multidrug resistance in cancer
2. Approaches to gene-directed enzyme prodrug therapy (GDEPT)
3. Prodrug activation enzymes in cancer gene therapy
4. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
5. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
6. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor
7. The bystander effect of the nitro-reductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite
8. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy
9. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect
10. Mammalian beta-glucuronidase: Genetics, molecular biology, and cell biology
11. Angiogenesis in cancer and other diseases
12. Biosynthesis of lysosomal hydrolases: Their synthesis in bound polysomes and the role of co- and post-translational processing in determining their subcellular distribution
13. Secreted human β-glucuronidase: A novel prodrug converting enzyme for gene therapy
14. Intracellular and cell surface displayed single-chain diabodies
15. Transmembrane orientation of signal-anchor proteins is affected by the folding state but not the size of the N-terminal domain
16. Definition and functional analysis of the signal/anchor domain of the human respiratory syncytial virus glycoprotein G
17. Tumor-selective prodrug activation by fusion protein-mediated catalysis
18. A novel one-step tumor-selective prodrug activation system
19. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy
20. Preclinical evaluation of the cardiac toxicity of HMMR-1826, a novel prodrug of doxorubicin
21. Elucidation of the mechanism enabling tumor selective prodrug monotherapy
22. Intensely cytotoxic anthracycline prodrugs: Glucuronides
23. Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard
24. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT
25. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer
26. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy
27. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy
28. Design and synthesis of water-soluble glucuroide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT)
29. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy
30. Cytochrome P450-based cancer gene therapy: Recent advances and future prospects
31. Periodic cdc25C transcription is mediated by a novel cell cycle-regulated repressor element (CDE)